nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2020 | editorial

Hepatocellular carcinoma

verfasst von: Dr. Angela Djanani

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Auszug

Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and the third most common cause of cancer-related death worldwide. Furthermore, it is the fastest growing cause of cancer-related death globally. …

Vorheriger Artikel Epithelial ovarian cancer

Nächster Artikel ESMO 2019: breast cancer

Putzer D, Schullian P, Eberle G, Bale R J. Thermal ablation—an option in curative treatment of HCC. memo. 2020;13(20). https://doi.org/10.1007/s12254-020-00600-5.CrossRef

Graziadei I. Systemic therapy in advanced-stage hepatocellular carcinoma. memo. 2020;13(2). https://doi.org/10.1007/s12254-020-00590-4.CrossRef

Hametner-Schreil S. Immunotherapy in hepatocellular carcinoma. memo. 2020;13(2). https://doi.org/10.1007/s12254-020-00592-2.CrossRef

Effenberger M, Tilg H. The intestinal microbiota and hepatocellular carcinoma. memo. 2020;13(2). https://doi.org/10.1007/s12254-020-00597-x.CrossRef

Titel: Hepatocellular carcinoma
verfasst von: Dr. Angela Djanani
Publikationsdatum: 01.06.2020
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00610-3

ESMO 2019—personal non-small lung cancer highlights

Open Access
short review

Screening for ovarian cancer: is there still hope?

Open Access
short review

The role of pathology in sarcoma

Open Access
short review

PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia

Open Access
original report

ESMO 2019: breast cancer

Open Access
short review

PARP inhibitors in the treatment of ovarian cancer

Open Access
review

Springer Medizin Österreich

Hepatocellular carcinoma

Auszug

Weitere Artikel der Ausgabe 2/2020

ESMO 2019—personal non-small lung cancer highlights

Screening for ovarian cancer: is there still hope?

The role of pathology in sarcoma

PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia

ESMO 2019: breast cancer

PARP inhibitors in the treatment of ovarian cancer

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

ESMO 2019—personal non-small lung cancer highlights

Screening for ovarian cancer: is there still hope?

The role of pathology in sarcoma

PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia

ESMO 2019: breast cancer

PARP inhibitors in the treatment of ovarian cancer